1. Market Research
  2. > Blood Cancer - Pipeline Review, H1 2013

Blood Cancer - Pipeline Review, H1 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 824 pages

Blood Cancer - Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Blood Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Blood Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Blood Cancer. Blood Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope


- A snapshot of the global therapeutic scenario for Blood Cancer.
- A review of the Blood Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Blood Cancer pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Blood Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Blood Cancer pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Blood Cancer - Pipeline Review, H1 2013
Table of Contents 2
Introduction 14
Blood Cancer Overview 15
Therapeutics Development 16
Blood Cancer Therapeutics under Development by Companies 18
Blood Cancer Therapeutics under Investigation by Universities/Institutes 45
Late Stage Products 51
Mid Clinical Stage Products 52
Early Clinical Stage Products 53
Discovery and Pre-Clinical Stage Products 54
Blood Cancer Therapeutics - Products under Development by Companies 55
Blood Cancer Therapeutics - Products under Investigation by Universities/Institutes 110
Companies Involved in Blood Cancer Therapeutics Development 119
Blood Cancer - Therapeutics Assessment 420
Drug Profiles 428
Blood Cancer Therapeutics - Drug Profile Updates 571
Blood Cancer Therapeutics - Discontinued Products 727
Blood Cancer Therapeutics - Dormant Products 743
Blood Cancer - Product Development Milestones 796
Appendix 810

List of Tables


Number of Products Under Development for Blood Cancer, H1 2013 29
Products under Development for Blood Cancer - Comparative Analysis, H1 2013 30
Number of Products under Development by Companies, H1 2013 32
Number of Products under Development by Companies, H1 2013 (Contd..1) 33
Number of Products under Development by Companies, H1 2013 (Contd..2) 34
Number of Products under Development by Companies, H1 2013 (Contd..3) 35
Number of Products under Development by Companies, H1 2013 (Contd..4) 36
Number of Products under Development by Companies, H1 2013 (Contd..5) 37
Number of Products under Development by Companies, H1 2013 (Contd..6) 38
Number of Products under Development by Companies, H1 2013 (Contd..7) 39
Number of Products under Development by Companies, H1 2013 (Contd..8) 40
Number of Products under Development by Companies, H1 2013 (Contd..9) 41
Number of Products under Development by Companies, H1 2013 (Contd..10) 42
Number of Products under Development by Companies, H1 2013 (Contd..11) 43
Number of Products under Development by Companies, H1 2013 (Contd..12) 44
Number of Products under Development by Companies, H1 2013 (Contd..13) 45
Number of Products under Development by Companies, H1 2013 (Contd..14) 46
Number of Products under Development by Companies, H1 2013 (Contd..15) 47
Number of Products under Development by Companies, H1 2013 (Contd..16) 48
Number of Products under Development by Companies, H1 2013 (Contd..17) 49
Number of Products under Development by Companies, H1 2013 (Contd..18) 50
Number of Products under Development by Companies, H1 2013 (Contd..19) 51
Number of Products under Development by Companies, H1 2013 (Contd..20) 52
Number of Products under Development by Companies, H1 2013 (Contd..21) 53
Number of Products under Development by Companies, H1 2013 (Contd..22) 54
Number of Products under Development by Companies, H1 2013 (Contd..23) 55
Number of Products under Development by Companies, H1 2013 (Contd..24) 56
Number of Products under Development by Companies, H1 2013 (Contd..25) 57
Number of Products under Investigation by Universities/Institutes, H1 2013 59
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 60
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 61
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..3) 62
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..4) 63
Comparative Analysis by Late Stage Development, H1 2013 64
Comparative Analysis by Mid Clinical Stage Development, H1 2013 65
Comparative Analysis by Early Clinical Stage Development, H1 2013 66
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 67
Products under Development by Companies, H1 2013 68
Products under Development by Companies, H1 2013 (Contd..1) 69
Products under Development by Companies, H1 2013 (Contd..2) 70
Products under Development by Companies, H1 2013 (Contd..3) 71
Products under Development by Companies, H1 2013 (Contd..4) 72
Products under Development by Companies, H1 2013 (Contd..5) 73
Products under Development by Companies, H1 2013 (Contd..6) 74
Products under Development by Companies, H1 2013 (Contd..7) 75
Products under Development by Companies, H1 2013 (Contd..8) 76
Products under Development by Companies, H1 2013 (Contd..9) 77
Products under Development by Companies, H1 2013 (Contd..10) 78
Products under Development by Companies, H1 2013 (Contd..11) 79
Products under Development by Companies, H1 2013 (Contd..12) 80
Products under Development by Companies, H1 2013 (Contd..13) 81
Products under Development by Companies, H1 2013 (Contd..14) 82
Products under Development by Companies, H1 2013 (Contd..15) 83
Products under Development by Companies, H1 2013 (Contd..16) 84
Products under Development by Companies, H1 2013 (Contd..17) 85
Products under Development by Companies, H1 2013 (Contd..18) 86
Products under Development by Companies, H1 2013 (Contd..19) 87
Products under Development by Companies, H1 2013 (Contd..20) 88
Products under Development by Companies, H1 2013 (Contd..21) 89
Products under Development by Companies, H1 2013 (Contd..22) 90
Products under Development by Companies, H1 2013 (Contd..23) 91
Products under Development by Companies, H1 2013 (Contd..24) 92
Products under Development by Companies, H1 2013 (Contd..25) 93
Products under Development by Companies, H1 2013 (Contd..26) 94
Products under Development by Companies, H1 2013 (Contd..27) 95
Products under Development by Companies, H1 2013 (Contd..28) 96
Products under Development by Companies, H1 2013 (Contd..29) 97
Products under Development by Companies, H1 2013 (Contd..30) 98
Products under Development by Companies, H1 2013 (Contd..31) 99
Products under Development by Companies, H1 2013 (Contd..32) 100
Products under Development by Companies, H1 2013 (Contd..33) 101
Products under Development by Companies, H1 2013 (Contd..34) 102
Products under Development by Companies, H1 2013 (Contd..35) 103
Products under Development by Companies, H1 2013 (Contd..36) 104
Products under Development by Companies, H1 2013 (Contd..37) 105
Products under Development by Companies, H1 2013 (Contd..38) 106
Products under Development by Companies, H1 2013 (Contd..39) 107
Products under Development by Companies, H1 2013 (Contd..40) 108
Products under Development by Companies, H1 2013 (Contd..41) 109
Products under Development by Companies, H1 2013 (Contd..42) 110
Products under Development by Companies, H1 2013 (Contd..43) 111
Products under Development by Companies, H1 2013 (Contd..44) 112
Products under Development by Companies, H1 2013 (Contd..45) 113
Products under Development by Companies, H1 2013 (Contd..46) 114
Products under Development by Companies, H1 2013 (Contd..47) 115
Products under Development by Companies, H1 2013 (Contd..48) 116
Products under Development by Companies, H1 2013 (Contd..49) 117
Products under Development by Companies, H1 2013 (Contd..50) 118
Products under Development by Companies, H1 2013 (Contd..51) 119
Products under Development by Companies, H1 2013 (Contd..52) 120
Products under Development by Companies, H1 2013 (Contd..53) 121
Products under Development by Companies, H1 2013 (Contd..54) 122
Products under Investigation by Universities/Institutes, H1 2013 123
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 124
Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 125
Products under Investigation by Universities/Institutes, H1 2013 (Contd..3) 126
Products under Investigation by Universities/Institutes, H1 2013 (Contd..4) 127
Products under Investigation by Universities/Institutes, H1 2013 (Contd..5) 128
Products under Investigation by Universities/Institutes, H1 2013 (Contd..6) 129
Products under Investigation by Universities/Institutes, H1 2013 (Contd..7) 130
Products under Investigation by Universities/Institutes, H1 2013 (Contd..8) 131
Bristol-Myers Squibb Company, H1 2013 132
Genzyme Corporation, H1 2013 133
Johnson and Johnson, H1 2013 134
Boehringer Ingelheim GmbH, H1 2013 135
F. Hoffmann-La Roche Ltd., H1 2013 136
Kyowa Hakko Kirin Co., Ltd., H1 2013 137
Biogen Idec Inc., H1 2013 138
Shionogi and Co., Ltd., H1 2013 139
Amgen Inc., H1 2013 140
Sanofi-Aventis, H1 2013 141
AstraZeneca PLC, H1 2013 142
Eli Lilly and Company, H1 2013 143
Viralytics Ltd., H1 2013 144
Athersys, Inc., H1 2013 145
GlaxoSmithKline plc, H1 2013 146
Seattle Genetics, Inc., H1 2013 147
Echo Therapeutics, Inc., H1 2013 148
Genentech, Inc., H1 2013 149
Biotec Pharmacon ASA, H1 2013 150
MedImmune LLC, H1 2013 151
Gilead Sciences, Inc., H1 2013 152
Daiichi Sankyo Company, Ltd, H1 2013 154
medac GmbH, H1 2013 155
Merck and Co., Inc., H1 2013 156
Dainippon Sumitomo Pharma Co., Ltd., H1 2013 157
Emergent BioSolutions Inc., H1 2013 158
Lentigen Corporation, H1 2013 159
Gamida Cell Ltd., H1 2013 160
Infinity Pharmaceuticals, Inc., H1 2013 161
Generex Biotechnology Corporation, H1 2013 162
Plexxikon Inc., H1 2013 163
BioLineRx, Ltd., H1 2013 164
Symphogen A/S, H1 2013 165
Amorfix Life Sciences Ltd., H1 2013 166
Reliance Life Sciences Pvt. Ltd., H1 2013 167
Piramal Healthcare Limited, H1 2013 168
Celltrion, Inc., H1 2013 169
Nanotherapeutics, Inc., H1 2013 170
Bio-Path Holdings, Inc., H1 2013 172
ZIOPHARM Oncology, Inc., H1 2013 173
Millennium Pharmaceuticals, Inc., H1 2013 174
Novartis AG, H1 2013 175
Aphios Corporation, H1 2013 176
Astellas Pharma Inc., H1 2013 177
BioMarin Pharmaceutical Inc., H1 2013 179
Chong Kun Dang Pharmaceutical, H1 2013 180
CK Life Sciences Int'l., (Holdings) Inc., H1 2013 181
Daewoong Pharmaceutical Co., Ltd., H1 2013 182
Eisai Co., Ltd., H1 2013 183
Gedeon Richter Plc., H1 2013 184
Genta Incorporated, H1 2013 185
Glenmark Pharmaceuticals Ltd., H1 2013 186
GTC Biotherapeutics, Inc., H1 2013 187
ImmunoGen, Inc., H1 2013 188
Nippon Kayaku Co., Ltd., H1 2013 189
Nippon Shinyaku Co., Ltd., H1 2013 190
Ono Pharmaceutical Co., Ltd., H1 2013 191
Pfizer Inc., H1 2013 192
Sigma-Tau S.p.A., H1 2013 193
Sunesis Pharmaceuticals, Inc., H1 2013 194
SuperGen, Inc., H1 2013 195
Taiho Pharmaceutical Co., Ltd., H1 2013 196
Teva Pharmaceutical Industries Limited, H1 2013 197
Cell Therapeutics, Inc., H1 2013 198
Genmab A/S, H1 2013 199
Sun Pharmaceutical Industries Limited, H1 2013 200
Enzon Pharmaceuticals, Inc., H1 2013 201
Sandoz Inc., H1 2013 202
Santaris Pharma A/S, H1 2013 203
Aduro BioTech, H1 2013 205
Cyclacel Pharmaceuticals Inc., H1 2013 206
Alfacell Corporation, H1 2013 207
Celgene Corporation, H1 2013 208

List of Figures


Number of Products under Development for Blood Cancer, H1 2013 29
Products under Development for Blood Cancer - Comparative Analysis, H1 2013 30
Products under Development by Companies, H1 2013 31
Products under Investigation by Universities/Institutes, H1 2013 58
Late Stage Products, H1 2013 64
Mid Clinical Stage Products, H1 2013 65
Early Clinical Stage Products, H1 2013 66
Discovery and Pre-Clinical Stage Products, H1 2013 67
Assessment by Monotherapy Products, H1 2013 433
Assessment by Combination Products, H1 2013 434
Assessment by Route of Administration, H1 2013 435
Assessment by Stage and Route of Administration, H1 2013 436
Assessment by Molecule Type, H1 2013 438
Assessment by Stage and Molecule Type, H1 2013 439

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.